List of Excipients in Branded Drug NAFCILLIN SODIUM

Generic Drugs Containing NAFCILLIN SODIUM

Company	Ingredient	NDC	Excipient
Sandoz Inc	nafcillin sodium	0781-3128	SODIUM CITRATE
Sandoz Inc	nafcillin sodium	0781-9224	SODIUM CITRATE
Armas Pharmaceuticals Inc	nafcillin sodium	72485-406	SODIUM CITRATE
Steriscience Specialties Private Limited	nafcillin sodium	82449-504	SODIUM CITRATE
ONESOURCE SPECIALTY PHARMA LIMITED	nafcillin sodium	83270-310	SODIUM CITRATE

What are the Most Frequently-Used Excipients in NAFCILLIN SODIUM?

# Of NDCs	Excipient
5	SODIUM CITRATE

Nafcillin Sodium Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Nafcillin sodium is an injectable, penicillinase-resistant beta-lactam used primarily for serious infections caused by methicillin-susceptible Staphylococcus aureus and other susceptible gram-positive organisms. Its commercial opportunity is concentrated in hospital injectable products, outpatient parenteral antimicrobial therapy, pharmacy-compounded delivery systems, and improved ready-to-administer formats.

The active ingredient is an old, largely generic molecule with limited conventional patent value. Product differentiation is more likely to come from excipient control, container-closure design, premixed delivery, stability, administration convenience, and supply reliability than from new chemical entity protection.

What is nafcillin sodium and how is it administered?

Nafcillin sodium is the sodium salt of nafcillin. It is administered by intravenous infusion or deep intramuscular injection. FDA labeling describes use for serious infections caused by penicillinase-producing staphylococci that remain susceptible to nafcillin.[1]

Attribute	Nafcillin sodium
Therapeutic class	Penicillinase-resistant penicillin
Dosage form	Sterile powder for injection; some products may be supplied as pharmacy bulk or premixed solutions
Common vial strengths	1 g and 2 g
Routes	Intravenous infusion and intramuscular injection
Primary institutional use	Serious MSSA infections
Typical adult dosing	1 to 2 g every four to six hours, depending on infection and clinical judgment
Main formulation challenge	Chemical stability after reconstitution or dilution
Main commercial channel	Hospital and specialty injectable markets

Nafcillin is generally selected when clinicians want an antistaphylococcal penicillin rather than vancomycin for susceptible S. aureus. Cefazolin is a major clinical and commercial competitor because it offers convenient dosing and broad hospital familiarity.

What excipients are used in nafcillin sodium injection?

The simplest nafcillin sodium injection products use few or no functional excipients in the dry powder. The vial generally contains nafcillin sodium, with the formulation relying on sterile water or a compatible infusion solution for reconstitution.

Core excipient categories

Excipient or material	Function	Commercial relevance
Sodium hydroxide or hydrochloric acid	pH adjustment during manufacture	Controls solubility, degradation, and product consistency
Sterile Water for Injection	Reconstitution vehicle	Required for preparation of the injectable solution
0.9% Sodium Chloride Injection	Diluent	Common hospital infusion vehicle
5% Dextrose Injection	Diluent	Alternative infusion vehicle, subject to stability limits
Container-closure elastomer	Maintains sterility and limits extractables	Important for long-term storage and particulate control
Glass vial	Primary container	Supports dry-powder stability and oxygen-moisture control

Product-specific inactive ingredients must be confirmed against the current label. Some nafcillin sodium labels identify no inactive ingredient other than materials used to adjust pH, while others may disclose formulation-specific components.[1,2]

A low-excipient formulation has advantages for parenteral safety and regulatory simplicity. It also limits opportunities to improve solubility, buffering, or liquid stability through conventional additive technology.

What formulation properties control nafcillin sodium stability?

Nafcillin sodium is sensitive to conditions that affect beta-lactam stability. The most important formulation variables are pH, temperature, concentration, diluent composition, storage duration, and exposure to light or reactive container materials.

pH and hydrolysis

Beta-lactam antibiotics can undergo hydrolysis in aqueous solution. The rate typically increases after reconstitution compared with the dry powder. A formulation strategy therefore needs to establish:

• pH at manufacture and after reconstitution
• potency over the labeled in-use period
• impurity profile, including degradation products
• stability at refrigerated and room temperatures
• compatibility with common infusion solutions
• acceptable particulate and color limits

The dry powder format avoids much of the instability associated with long-term storage in water. A ready-to-use liquid product would need a stronger stability package and may require a carefully selected buffer system, lower storage temperature, or specialized packaging.

Sodium burden

Nafcillin sodium contributes sodium to the administered dose. This matters in patients with heart failure, renal impairment, hypertension, or other conditions requiring sodium restriction. A product containing 1 g of nafcillin equivalent can impose a clinically relevant sodium load, depending on the salt composition and labeled dose.

A formulation with unnecessary sodium-containing buffers would increase that burden. Excipient selection should therefore avoid adding sodium beyond what is required for pH control, tonicity, or product performance.

Diluent compatibility

Hospital labels commonly identify compatible diluents such as 0.9% sodium chloride and 5% dextrose, but the permitted concentration and storage period depend on the specific product and preparation method.[1] Product development should test:

• Low and high concentrations used in adult and pediatric dosing
• Intermittent infusion and continuous infusion conditions
• Refrigerated storage followed by room-temperature administration
• Co-infusion through shared lines
• Compatibility with elastomeric pumps
• Adsorption to tubing and pump components
• Precipitation after temperature excursions

A label-supported stability window can have direct commercial value in outpatient parenteral antimicrobial therapy.

What excipient strategy is most attractive for nafcillin sodium?

The strongest strategy is usually a low-excipient sterile powder combined with validated reconstitution and administration instructions. This approach minimizes chemical risk and aligns with the established hospital workflow.

Strategy 1: Optimized lyophilized or sterile powder vial

A dry powder vial can be differentiated through:

• Faster reconstitution
• Lower foaming
• Reduced residual cake
• Improved vial withdrawal performance
• Longer shelf life
• Broader labeled diluent compatibility
• Smaller vial and lower shipping weight
• Latex-free and low-extractable packaging

A lyophilized formulation may improve cake structure and reconstitution time, but it also adds manufacturing cost and process-development requirements. The benefit must be demonstrated through stability, reconstitution, and handling data.

Strategy 2: Ready-to-administer premixed solution

A premixed IV bag can reduce pharmacy labor and compounding errors. It is particularly relevant for hospitals seeking standardized doses and for outpatient infusion providers.

Key development requirements include:

• Long-term liquid stability
• Stable potency through the intended shelf life
• Low particulate formation
• Compatibility with bag films and ports
• Low adsorption to administration sets
• Robustness to refrigerated transport
• Clear labeling of thawing and use periods if frozen
• Container-closure integrity

The commercial opportunity is stronger if the product can offer a shelf life materially longer than hospital-compounded preparations while maintaining a practical storage profile.

Strategy 3: Elastomeric-pump presentation

Nafcillin is used in prolonged outpatient treatment, where elastomeric pumps can reduce repeated daily preparation. A commercially useful product would need validated stability in the pump reservoir, delivery-rate consistency, and compatibility with the pump’s materials.

The most relevant excipient and material risks include:

• Drug loss to the reservoir or tubing
• Degradation during room-temperature exposure
• Pump membrane permeability
• Extractables and leachables
• Dose delivery variability over the infusion period

A pump-compatible presentation could compete on labor reduction rather than price per gram of active ingredient.

Strategy 4: Pharmacy bulk package

A pharmacy bulk package may support centralized hospital compounding. This option can reduce packaging cost per gram but increases the importance of aseptic handling, in-use dating, withdrawal procedures, and institutional pharmacy compliance.

What formulations are protected by nafcillin sodium patents?

Nafcillin sodium is an established generic injectable. The original compound and basic injectable formulation are outside the practical exclusivity period for a new chemical entity. Commercial protection is more likely to arise from product-specific formulation, device, packaging, or manufacturing patents than from the active ingredient itself.

Potentially protectable elements include:

Protectable element	Patent strength potential
Stable liquid formulation	Moderate if it solves a non-obvious stability problem
Specific buffer and pH range	Usually narrow; strength depends on unexpected results
Premixed IV bag	Moderate when combined with defined stability and container materials
Elastomeric-pump formulation	Moderate if stability and delivery performance are demonstrated
Low-sodium formulation	Potentially useful if it produces a measurable clinical or technical advantage
Lyophilization cycle	Usually process-specific and vulnerable to design-around
Container-closure system	Moderate for extractables, oxygen control, or delivery performance
Manufacturing process	Can be useful if it improves impurity control or yield

Patent value is strongest when claims cover a measurable product attribute, such as a defined impurity limit after extended storage, rather than a broad statement that nafcillin is stable in a common diluent.

What is the Orange Book status of nafcillin sodium?

Nafcillin sodium injectable products are generally marketed through abbreviated or legacy generic pathways rather than protected branded innovation. The Orange Book should be reviewed by product and application number because listing status can differ among approved injectable presentations.[3]

For a generic entrant, the principal regulatory questions are:

1. Whether the reference product has an active listed patent.
2. Whether a Paragraph IV certification is required.
3. Whether any listed patent covers the specific dosage form or delivery system.
4. Whether the proposed product is an ANDA product or a 505(b)(2) product.
5. Whether the formulation differs enough to require clinical or bridging data.

For a conventional sterile powder vial that matches an established reference product, formulation patents are unlikely to create a significant long-term barrier. A novel liquid, premixed, or device-integrated presentation may have a different regulatory and patent profile.

When does nafcillin sodium lose exclusivity?

The original molecule has long since lost ordinary small-molecule exclusivity. The practical market is generic, with competition determined by approvals, manufacturing capacity, hospital contracts, shortage conditions, and product convenience.

No biosimilar pathway applies because nafcillin sodium is a chemically synthesized small molecule, not a biologic. Biosimilar risk is therefore not relevant. The competitive threat comes from:

• Generic nafcillin sodium vials
• Cefazolin
• Oxacillin
• Vancomycin
• Daptomycin in selected clinical settings
• Oral step-down therapy when clinically appropriate

Nafcillin also competes with oxacillin as an antistaphylococcal penicillin. Oxacillin has similar clinical positioning but can differ in dosing, supply, formulary preference, and institutional experience.

Which companies are challenging or competing with nafcillin sodium?

The market is populated primarily by generic injectable manufacturers and hospital-supply companies. Relevant competitors may include manufacturers marketing nafcillin sodium for injection under generic labels, as well as companies supplying oxacillin, cefazolin, and vancomycin.

Competition is not limited to approved vial products. A manufacturer can gain share through:

• Reliable national supply
• Shorter lead times
• Large contract-pack sizes
• Premixed solutions
• Ready-to-administer syringes
• Pharmacy bulk packaging
• Extended stability after preparation
• Better shortage performance

The value of a new product is therefore tied to procurement economics and operational efficiency. A differentiated presentation must show a lower total cost of care, not simply a higher unit price.

What patent litigation and Paragraph IV risks affect nafcillin sodium?

Nafcillin sodium has a low apparent litigation profile compared with newer branded injectable drugs. A conventional generic vial is unlikely to face significant patent litigation if no active formulation or method-of-use patents are listed against the reference product.

Litigation risk rises for a company that develops:

• A novel stable liquid formulation
• A proprietary premixed bag
• A drug-device combination
• An extended-stability elastomeric pump
• A manufacturing process that is commercially important and separately patented

Paragraph IV risk should be assessed against active Orange Book listings at the time of filing. A product with no relevant listed patents may proceed through Paragraph III or a certification that no patent information is listed, depending on the application record and reference product.

What FDA regulatory pathway applies to new nafcillin sodium formulations?

Conventional vial

A conventional sterile powder vial generally fits the ANDA pathway if the product can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy injectable-product requirements. Injectable solutions and powders may receive bioequivalence treatment based on the dosage form and active ingredient, but product-specific FDA requirements control.

Premixed solution or new delivery system

A materially different liquid formulation, extended-stability product, or device-integrated presentation may require a 505(b)(2) strategy if it cannot rely fully on the reference product’s information. The regulatory value of a 505(b)(2) application depends on whether the formulation creates a clinically meaningful or operational advantage.

Important development packages include:

• Sterility and container-closure integrity
• Particulate matter testing
• Extractables and leachables
• Assay and degradation products
• Reconstitution or administration performance
• Stability under labeled conditions
• Compatibility with diluents and administration materials
• Human factors data for device presentations

How does nafcillin sodium compare with cefazolin and oxacillin?

Factor	Nafcillin sodium	Oxacillin	Cefazolin
Primary use	Serious MSSA infections	Serious MSSA infections	MSSA and other susceptible infections
Dosage convenience	Frequent dosing	Frequent dosing	Often less frequent dosing
Formulation opportunity	Premix, pump, stable liquid	Similar injectable opportunity	Broad existing injectable competition
Sodium considerations	Relevant	Relevant	Relevant
Hospital substitution risk	High	High	High
Commercial differentiation	Stability and administration	Supply and formulation	Convenience, cost, and broad use
Biosimilar risk	None	None	None

Cefazolin is often the stronger commercial comparator because less frequent administration can lower nursing and infusion costs. Nafcillin can remain attractive when clinicians prefer targeted antistaphylococcal therapy or when institutional protocols favor it.

What generic launch scenarios exist for nafcillin sodium?

Standard generic vial

This is the lowest-risk launch but also the most commoditized. Success depends on manufacturing reliability, procurement pricing, and access to group purchasing organizations.

Ready-to-use IV bag

This supports hospital labor savings and may gain share where pharmacy compounding capacity is constrained. The principal risks are liquid stability, packaging cost, and competition from hospital-prepared products.

Extended-stability outpatient product

This is the most commercially differentiated scenario. A product that remains stable through prolonged infusion and routine outpatient storage could target OPAT providers, home infusion pharmacies, and skilled nursing facilities.

Low-sodium presentation

A lower-sodium formulation may appeal to selected patient groups, but the commercial case requires a clearly quantified sodium reduction without sacrificing stability or increasing administration complexity.

How strong is the nafcillin sodium patent estate?

The core patent estate is weak for exclusivity purposes because the active ingredient and conventional injectable use are mature. A new entrant would likely obtain greater protection from formulation and delivery patents than from active-ingredient claims.

A commercially meaningful estate could combine:

1. A formulation patent covering pH, buffer, concentration, and impurity limits.
2. A container patent covering the bag, vial, syringe, or pump.
3. A process patent covering impurity control or sterile manufacture.
4. A method-of-use patent tied to a specific administration schedule or care setting, where legally supportable.

Method-of-use claims are less likely to provide strong protection for ordinary treatment of susceptible bacterial infections because the clinical use is well established. Geographic protection would need to be evaluated separately in the United States, Europe, Japan, and other markets, since patent term, listing rules, and generic approval procedures differ.

What are the main commercial opportunities for nafcillin sodium?

The strongest opportunities are operational:

• Premixed IV bags for inpatient use
• Ready-to-administer syringes for emergency and procedural settings
• Elastomeric-pump products for OPAT
• Longer post-reconstitution stability
• Reduced pharmacy preparation time
• Better cold-chain tolerance
• Contract-manufactured hospital supply
• Dual presentations for inpatient and outpatient channels

Revenue exposure is more likely to come from volume and contract retention than from premium pricing. Hospitals may accept a premium when the product reduces compounding labor, minimizes waste, prevents dosing errors, or improves availability during injectable antibiotic shortages.

Key Takeaways

• Nafcillin sodium is a mature generic injectable with little core-molecule exclusivity value.
• The most important formulation variables are pH, temperature, concentration, diluent, container materials, and post-reconstitution stability.
• A low-excipient dry powder vial is the lowest-risk formulation strategy.
• Premixed bags and elastomeric-pump products offer greater commercial differentiation.
• Sodium burden should be controlled because nafcillin sodium is used in patients who may have renal or cardiovascular comorbidities.
• No biosimilar pathway applies.
• Patent value is more likely to arise from formulation, packaging, device, or manufacturing claims than from method-of-use claims.
• Cefazolin is the principal commercial comparator because dosing convenience can reduce hospital administration costs.
• The strongest launch opportunity is an injectable product with validated extended stability and reduced pharmacy handling.

FAQs

Can nafcillin sodium be formulated as a ready-to-use liquid?

Yes. A ready-to-use liquid is technically feasible, but the product must control beta-lactam degradation, particulate formation, container interactions, and in-use stability. A premixed product would require a stronger stability package than a dry powder vial.

Is nafcillin sodium compatible with elastomeric infusion pumps?

Compatibility depends on the specific concentration, diluent, pump reservoir, tubing, temperature, and infusion duration. A commercial product requires product-specific stability and dose-delivery validation in the intended pump system.

Does nafcillin sodium require a preservative?

A single-dose sterile injectable generally does not require a preservative. Avoiding preservatives can simplify parenteral safety and reduce compatibility concerns. Multidose presentations would raise separate sterility and preservative requirements.

What is the best excipient for improving nafcillin sodium stability?

There is no universally preferred excipient. pH control, buffer selection, diluent composition, concentration, and packaging must be optimized together. Excessive buffering or sodium-containing excipients can increase sodium exposure without guaranteeing improved stability.

Can a new nafcillin sodium formulation receive meaningful patent protection?

Yes, but protection would likely be narrow and tied to a specific formulation, stability profile, container, delivery device, or manufacturing process. Broad protection over nafcillin sodium injection is unlikely for a mature generic product.

References

1. DailyMed. (n.d.). Nafcillin sodium injection, powder, for solution: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
4. U.S. Pharmacopeia. (2023). General chapter <797>: Pharmaceutical compounding, sterile preparations. United States Pharmacopeial Convention.